Sirolimus reduces cutaneous squamous cell carcinomas in transplantation recipients

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3297-3298

  Colegio, Oscar R ^a   Hanlon, Allison ^a   Olasz, Edit B ^b   Carucci, John A ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; RETINOL;

CANCER TRANSPLANTATION; CARCINOMATOSIS; CHEMOPROPHYLAXIS; DISEASE SEVERITY; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; NEPHROLOGIST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN ALLOGRAFT; SKIN CARCINOMA; SKIN EXAMINATION; FEMALE; MALE; NOTE; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; CARCINOMA, SQUAMOUS CELL; SKIN NEOPLASMS;

CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; SIROLIMUS; SKIN NEOPLASMS;

EID: 84891534505     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.6840     Document Type: Letter

References (8)

1. Krynitz B, Edgren G, Lindelö f B, et al: Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008: A Swedish population-based study. Int J Cancer 132:1429-1438, 2013.
2. Colegio OR, Hanlon A, Olasz EB, et al: Sirolimus reduces cutaneous squamous cell carcinomas in transplantation recipients. J Clin Oncol 31:3297- 3298, 2013.
3. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al: Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 31:1317-1323, 2013.
4. Euvrard S, Morelon E, Rostaing L, et al: Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329-339, 2012.
5. Campbell SB, Walker R, Tai SS, et al: Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 12:1146-1156, 2012.
6. Wisgerhof HC, Edelbroek JR, de Fijter JW, et al: Subsequent squamousand basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: Cumulative incidence and risk factors. Transplantation 89:1231-1238, 2010.
7. Hojo M, Morimoto T, Maluccio M, et al: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530-534, 1999.
8. Dantal J, Hourmant M, Cantarovich D, et al: Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 351:623-628, 1998. (Pubitemid 28098444)